

6-30-2022

The Overestimation of Concentric Hypertrophy In Patients With HFpEF as Determined By 2D-Echocardiography

Mohammad F. Mathbout
Medical University of South Carolina

Hussam Al Hennawi
Thomas Jefferson University

Anwar Khedr
Mayo Clinic Health System

Gaurang N. Vaidya
University of Kentucky

Marcus Stoddard
University of Louisville
Follow this and additional works at: <https://jdc.jefferson.edu/internalfp>

 Part of the [Internal Medicine Commons](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

Mathbout, Mohammad F.; Al Hennawi, Hussam; Khedr, Anwar; Vaidya, Gaurang N.; and Stoddard, Marcus, "The Overestimation of Concentric Hypertrophy In Patients With HFpEF as Determined By 2D-Echocardiography" (2022). *Division of Internal Medicine Faculty Papers & Presentations*. Paper 57. <https://jdc.jefferson.edu/internalfp/57>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Internal Medicine Faculty Papers & Presentations by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

The overestimation of concentric hypertrophy in patients with HFpEF as determined by 2D-echocardiography

Mohammad F. Mathbout, Hussam Al Hennawi*, Anwar Khedr, Gaurang N. Vaidya, Marcus Stoddard

*hussamhennawi.md@gmail.com

DOI: <https://doi.org/10.21542/gcsp.2022.11>
VOLUME: 2022
ISSUE: 1/2
ARTICLE: 11

PMC PUBLICATION DATE: 30 June 2022
PMC COLLECTION DATE: 30 June 2022
PMC ARTICLE TYPE: research-article

ARTICLE TYPE: Research article
SUBMITTED: 16 MAY 2022
ACCEPTED: 11 JUN 2022
RUNNING HEAD: Mathbout et al. GCSP 2022:11

CITE THIS ARTICLE AS: Mathbout MF, Al Hennawi H, Khedr A, Vaidya GN, Stoddard M. The overestimation of concentric hypertrophy in patients with HFpEF as determined by 2D-echocardiography, Global Cardiology Science and Practice 2022:11 <https://doi.org/10.21542/gcsp.2022.11>

COPYRIGHT: 2022 The Author(s), licensee Magdi Yacoub Institute. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Please note this is an 'Article in Press' and will be replaced with a typeset PDF & PubMed Central deposit in the coming weeks. Citation details and DOI will remain the same.

The overestimation of concentric hypertrophy in patients with HFpEF as determined by 2D-echocardiography

Mohammad F. Mathbout¹, Hussam Al Hennawi^{2*}, Anwar Khedr³, Gaurang N. Vaidya⁴, Marcus Stoddard⁵

1. *Medical University of South Carolina, Department of Cardiology; Charleston, South Carolina; USA.*
2. *Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA.*
3. *Department of Critical Care Medicine, Mayo Clinic Health System, Mankato, MN, USA.*
4. *University of Kentucky, Gill Heart Institute; Lexington, Kentucky, USA.*
5. *University of Louisville, Department of Cardiovascular Medicine; Louisville, Kentucky, USA.*

*hussamhennawi.md@gmail.com

Abstract

Background: Heart failure with preserved ejection fraction continues to pose multiple challenges in terms of accurate diagnosis, treatment, and associated morbidity. Accurate left ventricular (LV) mass calculation yields essential prognostic information relating to structural heart disease. Two-dimensional (2D) echocardiography-based calculations are solely limited to LV geometric assumptions of symmetry, whereas three-dimensional (3D) echocardiography could overcome these limitations. This study aims to compare the performance of 2D and 3D LV mass calculations.

Methods: A prospective review of echocardiography findings at the University of Louisville, Kentucky, was conducted and assessed. Normal ejection fraction (EF) was defined as $\geq 52\%$ in males and $\geq 54\%$ in females. The following calculations were performed: relative wall thickness (RWT) = $2 \times$ posterior wall thickness/LV internal diastolic dimension (LVIDd) and 2D LV mass = $0.8\{1.04([LVIDd + IVSd + PWd]^3 - LVIDd^3)\} + 0.6$. Concentric hypertrophy was RWT > 0.42 and LV mass > 95 kg/m² in females or > 115 kg/m² in males. The same cut-offs were used for 2D and 3D echocardiography.

Results: Echocardiographic findings for a total number of 154 patients in the study were investigated. There was a weak positive correlation between 2D and 3D LV mass indices ($R= 0.534$, $r^2= 0.286$, $p= 0.001$). Seventy patients had 3D EF $\geq 45\%$ with clinical heart failure (HFpEF). Among HFpEF patients, LV hypertrophy (LVH) was present in 74% of patients by 2D echocardiography and 30% by 3D echocardiography (McNemar test $p= 0.001$). Using 3D echocardiography as the reference, 68% of normal patients were misdiagnosed with LV hypertrophy by 2D echocardiography. Two-thirds of the patients with concentric remodeling by 3D echocardiography were misclassified as having concentric hypertrophy by 2D echocardiography ($p=0.001$).

Conclusion: Adapting necropsy-proven LV mass index cutoffs, 2D over-diagnosed LV hypertrophy through overestimation of the mass, compared to 3D echocardiography. In turn, the majority of HFpEF patients showed no structural hypertrophy of the LV on 3D imaging. This suggests that the majority of patients with HFpEF may qualify for pharmacological prevention to prevent further progression to LV remodeling or LVH.

Background

Among different parameters used to assess left ventricular (LV) function, left ventricular ejection fraction (LVEF) remains the most widely used echocardiographic parameter which provides an independent predictor of mortality and further direct patient management [1-3]. Operator-dependent 2-dimensional (2D) and 3-dimensional (3D) echocardiographic imaging provides both quantitative and qualitative assessments of the LV hemodynamic functions necessary for optimal cardiac evaluation. While both can assess LVEF, 2D echocardiography LVEF assessment is largely dependent on the reader's experience and imaging plane with varying accuracy according to imaging quality [4]. Newly emerged techniques used for LV functional evaluation include temporal speckle-tracking echocardiography (STE), which depicts LV myocardial deformation parameters, including global longitudinal strain (GLS). Unlike EF evaluation, GLS provides reproducible readings subject to subtle changes in LV function prior to imminent changes in EF in different disease states amenable to medical treatment [5, 6]. Moreover, different studies have reported more accurate mortality predictions associated with GLS than with EF [7-10].

Although most outcome predicting studies have utilized 2D echocardiography (2DE) to evaluate LV function, 3D echocardiography (3DE) has been shown to provide

superior LV size and function evaluations in terms of reproducibility and function [11]. This is largely due to overcoming apical foreshortening and the acquisition of measurements that are mainly based on direct volumetric measurements in the absence of geometrical presumptions. Of note, in the era of imaging advances, growing evidence has shown that 3DE has provides better visualization of LV morphology analysing different parameters including relative wall thickness (RWT) outlining early stages of myocardial hypertrophy confidently tied with further diagnostic and prognostic outcomes [12, 13]. Therefore, we hypothesized that 3DE analytical tools can better predict ensuing myocardial changes in patients with HFpEF, making them candidates for an early course of pharmacological treatment.

Methods

A prospective review of echocardiography findings at the University of Louisville, Kentucky, was conducted and assessed. Normal ejection fraction (EF) was defined as $\geq 52\%$ in males and $\geq 54\%$ in females. The following calculations were performed: relative wall thickness (RWT) = $2 \times$ posterior wall thickness/LV internal diastolic dimension (LVIDd) and 2D LV mass = $0.8\{1.04([LVIDd + IVSd + PWd]^3 - LVIDd^3)\} + 0.6$. Concentric hypertrophy was RWT > 0.42 and LV mass > 95 kg/m² in females or > 115 kg/m² in males. Same cutoffs were used for 2D and 3D echocardiography.

Results

Echocardiographic findings for a total number of 154 patients in the study were investigated. There was a weak positive correlation between the 2D and 3D LV mass indices (R= 0.534, r²= 0.286, P = 0.001) (figure 1). Seventy patients had 3D EF $\geq 45\%$ with clinical heart failure (HFpEF). Among HFpEF patients, LV hypertrophy (LVH) was present in 74% of patients by 2D and 30% by 3D echocardiography (McNemar test p= 0.001). Using 3D echocardiography as the reference, 68% of the normal patients were misdiagnosed as LV hypertrophy by 2D (**Table 1**). Two-thirds of the patients with concentric remodeling by 3D echocardiography were misclassified as having concentric hypertrophy by 2D echocardiography (p=0.001).

	2D interpretation	P-value

		Normal	LV Hypertrophy	
3D interpretation	Normal	16 (32%)	33 (68%)	0.04
	LV Hypertrophy	2 (10%)	19 (90%)	

Table 1. Comparison of 2D and 3D interpretation of LV mass index.




Figure 1. Comparison of 2D and 3D LV mass index.

Discussion

The pathogenesis of HFpEF is still not completely understood. The pathophysiology of HFpEF can be explained by two theories. The old conventional theory holds that systemic hypertension is the primary cause of left ventricular remodeling. Concentric left ventricular hypertrophy, fibrosis, and diastolic dysfunction result from pressure

overload, leading to left atrial hypertension and remodeling. These processes can lead to pulmonary hypertension and atrial fibrillation. Finally, diastolic dysfunction in the left ventricle causes right ventricular and atrial remodeling, as well as concomitant right ventricular diastolic and systolic dysfunction [14, 15]. In addition to systemic hypertension, a novel emerging theory considers metabolic disorders such as obesity, metabolic syndrome, and type 2 diabetes mellitus. These pro-inflammatory comorbidities produce microvascular endothelial inflammation. This results in coronary microvascular inflammation, decreased density, cardiac interstitial fibrosis, and increased oxidative stress, leading to cardiomyocyte hypertrophy and stiffness. The previous factors result in myocardial hypertrophy, remodeling, and dysfunction [14, 16, 17].

Left ventricular wall remodeling is considered one of the most important pathophysiological factors predisposing to overt heart failure. Different patterns of left ventricular (LV) remodeling have been described, including normal geometry, concentric remodeling, concentric hypertrophy, and eccentric hypertrophy. Stemming from geometrical changes that can be detected at earlier stages, the current consensus on LV chamber measurements advises the characterization of LV geometry based on echocardiographically determined LV mass index (LVMI) and relative wall thickness (RWT) [18]. Healthy geometry is identified by normal LVMI and RWT. Compared to other disorders, concentric remodeling is characterized by increased RWT, whereas both eccentric and concentric hypertrophy are marked by increased LVMI with normal RWT in the former and increased RWT in the latter. Moreover, concentric hypertrophy can be differentiated by an increase in short-axis diameter compared to an increase in myocyte length in eccentric hypertrophy, which is evident microscopically [19]. Although LV geometric abnormalities can be detected at early stages of LV remodeling, heart failure has over the years been staged by LV ejection fraction (LVEF) instead of LV geometry. This has recently conflicted with experts' opinions recommending that early recognition of geometric abnormalities can preserve normal heart function and provide accurate estimation beyond what is expected from ejection fraction alone [20].

Left ventricular remodeling and hypertrophy were found to be the most common abnormal geometric abnormalities in patients with HFpEF in most epidemiological studies, registries, and clinical trials (Tables 2, 3) [21-27]. In addition, patients with HFpEF are reported to have more prominent concentric hypertrophy than those with hypertensive heart disease who do not have HFpEF [12(28)]. It was also found that LVH had a reverse correlation with exercise capacity. Among all geometric types,

patients with LV concentric hypertrophy showed the greatest exercise limitation due to reduced contractility and chronotropic incompetence [29]. Moreover, LVH was found to be a strong predictor of heart failure hospitalization, cardiovascular death, or aborted cardiac arrest. In this study, LV concentric remodeling and hypertrophy were the most common abnormal geometric findings associated with an increased risk of hospitalizations inferred from the TOPCAT trial [27].

	Normal geometry	Left ventricular remodeling	Left ventricular concentric hypertrophy	Left ventricular eccentric hypertrophy
Olmsted County [5]	31 %	27 %	26 %	16 %
ARIC study [6]	5 %	20 %	73 %	2 %
Northwestern registry [7]	12 %	28 %	48 %	12 %

Table 2. Prevalence of LV concentric remodeling and hypertrophy in patients with HFpEF in selected epidemiological studies and registries.

	Normal geometry	Left Ventricular remodeling	Left ventricular concentric hypertrophy	Left ventricular eccentric hypertrophy
PARAMOUNT [8]	72 %	14 %	7 %	7 %
I-PRESERVE [9]	46 %	25 %	29 %	0 %
PARAGON-HF [10]	46 %	33 %	12 %	9 %
TOPCAT [11]	14 %	34 %	43 %	9 %

Table 3. Prevalence of LV concentric remodeling and hypertrophy in selected HFpEF clinical trials.

Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome that accounts for half of all heart failure (HF) patients and has been increasing in prevalence attributing to major cardiovascular mortality [30]. HFpEF expands beyond abnormalities strictly to LV diastolic function and is considered a spectrum of diseases that encompasses limitations in cardiac, vascular, and peripheral functions [30]. On the other hand, LV diastolic dysfunction plays a cardinal role in the pathophysiology of HFpEF [31]. LV diastolic dysfunction is characterized by an impairment of heart muscle relaxation, an increase in viscoelastic chamber stiffness (decreased compliance), or a combination of the two [32, 33]. This results in symptomatic HF stemming from the congestion of the vascular system and other vital organs, giving rise to a range of symptoms, including dyspnea, impairment of daily activities at rest, and exertion.

Hemodynamic impairments associated with circulatory pump failure predispose patients to recurrent hospitalization, diminished quality of life (QoL), and decreased survival. Early HFpEF phenotyping is crucial to halt further progression and may impart necessary measures for targeted therapies to this specific subpopulation of patients positioned to attain the greatest benefit [31]. Cardiovascular imaging, and echocardiography in particular, plays a vital role in the diagnosis and assessment of HFpEF, which evaluates cardiac structure, hemodynamics, and function [34]. While the diagnosis of HFpEF is clear in symptomatic patients with signs of overt congestion, diagnosing euvolemic patients with marked exertional dyspnea poses a considerable challenge [35-37].

Conclusion

HFpEF continues to pose multiple challenges concerning accurate diagnosis, treatment, and associated morbidity. Cardiovascular imaging provides important information necessary for accurate diagnosis at early stages in patients who may require treatment to halt further progression. In particular, echocardiography assesses cardiac function and accurately identifies abnormal geometric changes; therefore, clinical suspicion warrants evaluation.

Since LV remodeling and concentric hypertrophy are the most common geometric changes in HFpEF and constitute the cornerstone of HFpEF pathogenesis, it is essential to identify these changes before progression to more advanced stages. This study adds value to the diagnostic and prognostic utility of 3D echocardiographic functional indices to identify LV remodeling and concentric hypertrophy early in order to risk-stratify patients and drive their management accordingly.

References

1. Nelson GR, Cohn PF, Gorlin R. Prognosis in medically-treated coronary artery disease: influence of ejection fraction compared to other parameters. *Circulation*. 1975;52(3):408-412. doi:10.1161/01.cir.52.3.408
2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med*. 2002;346(12):877-883. doi:10.1056/NEJMoa013474
3. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. *Circulation*. 2005;112(24):3738-3744. doi:10.1161/CIRCULATIONAHA.105.561423
4. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, Josephson ME, Lehmann MH, Prystowsky EN. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. *J Am Coll Cardiol*. 2007;50(12):1150-1157. doi:10.1016/j.jacc.2007.04.095
5. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. *Heart*. 2014;100(21):1673-1680. doi:10.1136/heartjnl-2014-305538
6. Morris DA, Otani K, Bekfani T, Takigiku K, Izumi C, Yuda S, Sakata K, Ohte N, Tanabe K, Friedrich K, Kühnle Y, Nakatani S, Otsuji Y, Haverkamp W, Boldt LH, Takeuchi M. Multidirectional global left ventricular systolic function in normal subjects and patients with hypertension: multicenter evaluation. *J Am Soc Echocardiogr*. 2014;27(5):493-500. doi:10.1016/j.echo.2014.01.017
7. Nahum J, Bensaid A, Dussault C, Macron L, Clémence D, Bouhemad B, Monin JL, Rande JL, Gueret P, Lim P. Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients. *Circ Cardiovasc Imaging*. 2010;3(3):249-256. doi:10.1161/CIRCIMAGING.109.910893

8. Motoki H, Borowski AG, Shrestha K, Troughton RW, Tang WH, Thomas JD, Klein AL. Incremental prognostic value of assessing left ventricular myocardial mechanics in patients with chronic systolic heart failure. *J Am Coll Cardiol.* 2012;60(20):2074-2081. doi:10.1016/j.jacc.2012.07.047
9. Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Velazquez EJ, Hassager C, Søgaard P, Køber L. Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. *J Am Coll Cardiol.* 2013;61(23):2365-2373.
10. Krishnasamy R, Isbel NM, Hawley CM, Pascoe EM, Burrage M, Leano R, Haluska BA, Marwick TH, Stanton T. Left Ventricular Global Longitudinal Strain (GLS) Is a Superior Predictor of All-Cause and Cardiovascular Mortality When Compared to Ejection Fraction in Advanced Chronic Kidney Disease. *PLoS One.* 2015;10(5):e0127044. Published 2015 May 15. doi:10.1371/journal.pone.0127044
11. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. *J Am Coll Cardiol.* 2012;59(20):1799-1808. doi:10.1016/j.jacc.2012.01.037
12. Maffessanti F, Caiani EG, Tamborini G, Muratori M, Sugeng L, Weinert L, Alamanni F, Zanobini M, Mor-Avi V, Lang RM, Pepi M. Serial changes in left ventricular shape following early mitral valve repair. *Am J Cardiol.* 2010;106(6):836-842. doi:10.1016/j.amjcard.2010.04.044
13. Vadakkumpadan F, Trayanova N, Wu KC. Image-based left ventricular shape analysis for sudden cardiac death risk stratification. *Heart Rhythm.* 2014;11(10):1693-1700. doi:10.1016/j.hrthm.2014.05.018
14. Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. *Pflugers Arch.* 2014;466(6):1037-1053. doi:10.1007/s00424-014-1480-8

15. Redfield MM. Heart Failure with Preserved Ejection Fraction. *N Engl J Med*. 2016;375(19):1868-1877. doi:10.1056/NEJMcp1511175
16. Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions. *Heart*. 2018;104(5):377-384. doi:10.1136/heartjnl-2016-310790
17. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol*. 2013;62(4):263-271. doi:10.1016/j.jacc.2013.02.092
18. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1-39.e14. doi:10.1016/j.echo.2014.10.003
19. Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. *Nat Rev Cardiol*. 2018;15(7):387-407. doi:10.1038/s41569-018-0007-y
20. Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Baks J, Bauersachs J, Burkhoff D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Hulot JS, Konstam M, Lee RT, Linke WA, Lunde IG, Lyon AR, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parissis J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochu JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW. The continuous heart failure spectrum: moving beyond an ejection fraction classification. *Eur Heart J*. 2019;40(26):2155-2163. doi:10.1093/eurheartj/ehz158
21. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons

with heart failure and preserved ejection fraction from Olmsted County, Minnesota [published correction appears in *Circulation*. 2007 May 22;115(20):e535]. *Circulation*. 2007;115(15):1982-1990. doi:10.1161/CIRCULATIONAHA.106.659763

22. Gupta DK, Shah AM, Castagno D, Takeuchi M, Loehr LR, Fox ER, Butler KR, Mosley TH, Kitzman DW, Solomon SD. Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study. *JACC Heart Fail*. 2013;1(2):156-163. doi:10.1016/j.jchf.2013.01.003
23. Katz DH, Beussink L, Sauer AJ, Freed BH, Burke MA, Shah SJ. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. *Am J Cardiol*. 2013;112(8):1158-1164. doi:10.1016/j.amjcard.2013.05.061
24. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *Lancet*. 2012;380(9851):1387-1395. doi:10.1016/S0140-6736(12)61227-6
25. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. *Circulation*. 2011;124(23):2491-2501. doi:10.1161/CIRCULATIONAHA.110.011031
26. Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. *J Am Coll Cardiol*. 2019;74(23):2858-2873. doi:10.1016/j.jacc.2019.09.063
27. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction:

findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. *Circ Heart Fail.* 2014;7(5):740-751.

doi:10.1161/CIRCHEARTFAILURE.114.001583

28. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. *J Am Coll Cardiol.* 2007;49(2):198-207. doi:10.1016/j.jacc.2006.08.050
29. Lam CS, Grewal J, Borlaug BA, Ommen SR, Kane GC, McCully RB, Pellikka PA. Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity. *Hypertension.* 2010;55(5):1143-1149. doi:10.1161/HYPERTENSIONAHA.109.146845
30. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med.* 2006;355(3):251-259. doi:10.1056/NEJMoa052256
31. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol.* 2014;11(9):507-515. doi:10.1038/nrcardio.2014.83
32. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications [published correction appears in *J Am Coll Cardiol* 1993 Oct;22(4):1272]. *J Am Coll Cardiol.* 1993;22(1):318-325. doi:10.1016/0735-1097(93)90850-z
33. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. *Annu Rev Med.* 2004;55:373-394. doi:10.1146/annurev.med.55.091902.104417
34. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular

Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29(4):277-314.
doi:10.1016/j.echo.2016.01.011

35. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. *Circulation*. 2018;138(9):861-870.
doi:10.1161/CIRCULATIONAHA.118.034646
36. Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. *Circulation*. 2017;135(9):825-838.
doi:10.1161/CIRCULATIONAHA.116.024822
37. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. *Circ Heart Fail*. 2010;3(5):588-595.
doi:10.1161/CIRCHEARTFAILURE.109.930701

